DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia

Information source: Universidad de Granada
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fibromyalgia

Intervention: trazodone, pregabalin (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Universidad de Granada

Official(s) and/or principal investigator(s):
Elena P Calandre, MD, Principal Investigator, Affiliation: Universidad de Granada

Overall contact:
Elena P. Calandre, MD, Phone: +34 958246291, Email: calandre@gmail.com


The study has a double purpose: a first phase intends to assess the effectiveness and tolerability of trazodone, an antidepressant with sedative and sleep-promoting properties, in the treatment of fibromyalgia; a second phase intends to evaluate if the addition of pregabalin to patients who have shown a partial response to trazodone additionally improves fibromyalgia symptomatology.

Clinical Details

Official title: Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)

Study design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome: Mean decrease, from baseline to endpoint, in the Fibromyalgia Impact Questionnaire

Secondary outcome:

Change from baseline to endpoint in the scores of the Pittsburgh Sleep Quality Inventory, the Brief Pain Inventory, the Beck Depression Inventory, and the Hospital Anxiety and Depression Scale

Discontinuation rates due to treatment-related adverse events, proportion of patients experiencing any adverse event, proportion of patients experiencing serious adverse events


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- patients diagnosed of fibromyalgia according to the American College of Rheumatology


- written, informed consent

- able to understand and comply with the requirements of the study

Exclusion Criteria:

- pregnancy or breastfeeding

- unwillingness to discontinue other prescribed medications before entering in the


- patients who had previously received trazodone without improvement or who did not

tolerate the drug

- patients who had previously received pregabalin without improvement or who did not

tolerate the drug (only for the phase II of the study)

Locations and Contacts

Elena P. Calandre, MD, Phone: +34 958246291, Email: calandre@gmail.com

Instituto de Neurociencias, Granada 18012, Spain; Recruiting
Piedad Morillas-Arques, MD, Sub-Investigator
Carmen Rodriguez-Lopez, MD, Sub-Investigator
RocĂ­o Molina-Barea, MD, Sub-Investigator
Juan S. Vilchez, MD, Sub-Investigator
Additional Information

Web page of the Institute of Neuroscience of the University of Granada

Starting date: April 2008
Ending date: June 2009
Last updated: November 13, 2008

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015